Stock Market Reviews

Read and share opinions on SCYX (SCYNEXIS, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
  This cross-disciplinary meeting highlights the latest discoveries, technologies and translational strategies driving the next generation of antimicrobial solutionsJERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations highlighting data on the Company’s second-generation fungerp drug candidate, SCY-247
  Jan 28, 2026
• SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
  The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant, Candida auris fungal infection JERSEY CITY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration
  Jan 21, 2026
• SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
  JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market (“Nasdaq”) to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2). The Company now has until June 15, 2026, to meet the require
  Dec 22, 2025
• SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
  GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low to mid single digit range JERSEY CITY, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the
  Nov 19, 2025
• Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
  Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company’s next generation of triterpenoid antifungals (fungerps).Next-generation fungerps, in preclinical stages of development, are targeted to have enhanced pharmacological properties to treat fungal infections where current therapies are limited or not effective, while maintaining broad spectrum of activity against
  Nov 17, 2025
• Here's Why We're A Bit Worried About SCYNEXIS' (NASDAQ:SCYX) Cash Burn Situation
  We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
  Nov 10, 2025
• SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
  SCYNEXIS to receive one-time payments totalling $24.8 million from GSK as part of the resolution of the disagreement related to the restart of the Phase 3 MARIO study in invasive candidiasis. Scynexis agreed to GSK’s request to terminate the study.Following the positive SAD/MAD data results announced in September for SCY-247, its second-generation fungerp, the Company expects to initiate a Phase 1 study with the IV formulation and a Phase 2 study for the treatment of invasive candidiasis. The Co
  Nov 5, 2025
• Scynexis: Q3 Earnings Snapshot
  JERSEY CITY, N.J. (AP) — Scynexis Inc. SCYX) on Wednesday reported a loss of $8.6 million in its third quarter. The Jersey City, New Jersey-based company said it had a loss of 17 cents per share.
  Nov 5, 2025
• SCYNEXIS Reports Positive Phase 1 Results for Second-Generation Antifungal SCY-247
  SCYNEXIS Inc. (NASDAQ:SCYX) is one of the best long term penny stocks with huge upside potential. On September 30, SCYNEXIS announced positive results from a Phase 1 clinical study evaluating SCY-247, its second-generation triterpenoid antifungal compound. The candidate is being developed for the treatment and prevention of invasive fungal infections to provide the therapeutic advantages […]
  Oct 24, 2025
• SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
  SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasisScynexis will promptly wind-down and terminate the MARIO studyThe payment from GSK, combined with cash in hand and removal of future MARIO expenditures, extends the company’s cash runway to more than two yearsGSK remains committed to the commercialization of BREXAFEMME (ibrexafungerp tablets) JERSEY CITY, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, In
  Oct 15, 2025
• SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)
  No safety concerns or dose limiting toxicities observed SCY-247 was able to achieve target exposures at doses lower than our first-generation fungerp Safety, tolerability, and pharmacokinetic profile support the continued clinical development of SCY-247 JERSEY CITY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced positive result
  Sep 30, 2025
• SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
  Oral presentation will feature data demonstrating SCY-247 in vitro activity against C. auris strains, including isolates with mutations commonly associated with echinocandin-resistanceAdditional poster presentations highlight SCY-247’s broad spectrum of antifungal activity, against Candida species, including multidrug- and pandrug-resistant C. auris and Aspergillus speciesCompany anticipates reporting Phase 1 Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) data for SCY-247 (oral) in Q3 2
  Sep 4, 2025
• SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
  JERSEY CITY, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Scynexis senior leadership team will participate in the H.C. Wainwright 27th Annual Global Conference. Date: Wednesday September 10, 2025Format: In-person presentation and 1x1 meetingsTime: 10:30 a.m.-11:00 a.m. ETLocation: New York, NY If you are interested in
  Aug 25, 2025
• SCYNEXIS Second Quarter 2025 Earnings: Beats Expectations
  SCYNEXIS ( NASDAQ:SCYX ) Second Quarter 2025 Results Key Financial Results Net loss: US$6.89m (loss narrowed by 52...
  Aug 15, 2025
• SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
  First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six month anniversary of the new patient dosing; as previously disclosed GSK disputes these milestone payments. SCYNEXIS vigorously disagrees with GSK’s position and is working towards resolving this disagreement; SCYNEXIS is actively working with GSK to transfer the BREXAFEMME New Drug Application (ND
  Aug 13, 2025
• Scynexis: Q2 Earnings Snapshot
  JERSEY CITY, N.J. (AP) — Scynexis Inc. SCYX) on Wednesday reported a loss of $6.9 million in its second quarter. The Jersey City, New Jersey-based company said it had a loss of 14 cents per share.
  Aug 13, 2025
• SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold
  SCYNEXIS, Inc. (NASDAQ:SCYX) has officially restarted patient dosing in its Phase III MARIO trial for Brexafemme (ibrexafungerp) after the FDA lifted a nearly two-year clinical hold. The hold, initiated over concerns of beta-lactam contamination at the original manufacturing facility, was removed once new drug batches were produced at a separate location. With trial sites now […]
  May 29, 2025
• Scynexis resumes dosing in Phase III MARIO study after lengthy delay
  The trial continuation comes amid uncertain times between Scynexis and licensing partner GSK.
  May 28, 2025
• SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
  First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical holdResumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six months; as previously disclosed GSK disputes these milestone payments, and SCYNEXIS vigorously disagrees with their position JERSEY CITY, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prev
  May 28, 2025
• SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
  Ibrexafungerp clinical hold lifted by the FDA. SCYNEXIS working to resolve a disagreement with GSK involving the restart of the MARIO study. GSK remains committed to the commercialization of Brexafemme.Hansoh recently received Chinese (NMPA) approval for ibrexafungerp in the treatment of acute VVC. SCYNEXIS will receive a milestone payment from Hansoh upon commercialization as well as royalties of approximately 10% on China sales.Presented positive preclinical data for its second-generation fung
  May 15, 2025

• TrendHunter

  Feb 13, 2026

  $SCYX Sitting on the sidelines while competitors run laps.

  Sell

• FiscalRiot

  Feb 13, 2026

  $SCYX A race against time! This company is sprinting towards crucial milestones, but can they deliver? The tension is palpable as investors watch and wait for the next big move!

  Buy

• BullishBerserker

  Feb 12, 2026

  $SCYX In the fight against infections, every day counts! Will this company become a pioneer or fall behind in the race? The suspense is unbearable!

  Sell

• CapitalCreep

  Feb 12, 2026

  $SCYX This company’s got more problems than solutions.

  Sell

• TradeTracer

  Feb 12, 2026

  $SCYX The ongoing advancements in their clinical pipeline suggest a robust potential for impactful contributions to healthcare. Their focus on addressing unmet medical needs is commendable.

  Buy

• CryptoCobra

  Feb 12, 2026

  $SCYX Fighting fungal infections like a superhero but with way less spandex. Because who needs that drama in life, right?

  Buy

• DividendDemon

  Feb 12, 2026

  $SCYX Fighting infections like an action hero in a blockbuster movie. Cue the dramatic music and slow-motion!

  Buy

• FiscalRogue

  Feb 11, 2026

  $SCYX Chasing diseases while missing the cure for poor management.

  Sell

• MarginMeme

  Feb 10, 2026

  $SCYX In the lab cooking up something serious, keep an eye on this!

  Buy

• GammaSlayer

  Feb 10, 2026

  $SCYX Stuck in clinical trials while the world moves on.

  Sell

• MemeInvestor

  Feb 9, 2026

  $SCYX Like a superhero, this stock jumps in to save the day—just make sure it doesn’t take too long to arrive!

  Buy

• TrendStalker

  Feb 9, 2026

  $SCYX Another promising concept that went nowhere.

  Sell

• BearHunter

  Feb 9, 2026

  $SCYX They must have a killer strategy because they're making waves like it's a surf competition!

  Buy

• TheRiskDealer

  Feb 9, 2026

  $SCYX With the healthcare landscape shifting dramatically, this player is in a tight spot. Will it adapt quickly enough to stay afloat? The stakes couldn't be higher!

  Buy

• MemeInvestor

  Feb 7, 2026

  $SCYX This company is like trying to get the last slice of pizza—everyone's fighting for it, but it’s totally worth it!

  Sell

• FinTechNomad

  Feb 7, 2026

  $SCYX Among a sea of uncertainty, this firm is making waves! But will their efforts pay off or will they sink under the weight of their ambitions?

  Buy

• AlgoAce

  Feb 7, 2026

  $SCYX If this company were a movie, it’d be a thriller—full of unexpected twists and turns! Popcorn ready?

  Buy

• FinTechNomad

  Feb 7, 2026

  $SCYX As the healthcare landscape shifts dramatically, this stock could either revolutionize treatment or fade away into obscurity. The clock is ticking!

  Sell

• TradePhantom

  Feb 7, 2026

  $SCYX This biotech firm is like a half-baked idea gone wrong.

  Sell

• TheAlphaDagger

  Feb 6, 2026

  $SCYX In the high-stakes field of biotech, this company is hoping to cure the uncurable. Will they be the next breakthrough or just another missed opportunity? It’s a nail-biter!

  Buy

• PnLPhantom

  Feb 6, 2026

  $SCYX Hold onto your hats! This stock is volatile and could take a dramatic turn. The excitement is palpable, but so is the risk!

  Buy

• GainSurge

  Feb 6, 2026

  $SCYX This biotech stock is like walking a tightrope over a pit of alligators. One miscalculation could spell disaster, so be vigilant!

  Sell

• FiscalEngine

  Feb 5, 2026

  $SCYX Focused on innovative antifungal therapies, this organization is making strides in a niche yet vital area of healthcare. With the growing emphasis on combating resistant infections, its research could lead to significant breakthroughs.

  Buy

• StonkDestroyer

  Feb 5, 2026

  $SCYX Another biotech with a long way to go and no edge.

  Sell

• MarginDagger

  Feb 4, 2026

  $SCYX This firm is pioneering treatments in infectious diseases, demonstrating an unwavering focus on addressing urgent health threats. Their advancements could play a vital role in improving patient care and outcomes in global health.

  Buy

• TheStockKnight

  Feb 4, 2026

  $SCYX A biopharma with promise—too bad it's all just talk.

  Sell

• QuantumBroker

  Feb 4, 2026

  $SCYX This biotech firm is riding a rollercoaster of highs and lows, and the stakes are impossibly high! One breakthrough could skyrocket it, but the pressure is palpable. Are you ready for the ride?

  Buy

• BearishBoi

  Feb 3, 2026

  $SCYX This company’s moves are slicker than a cat on a hot tin roof—definitely keeping things interesting!

  Buy

• BullRunBoss

  Feb 3, 2026

  $SCYX Their solutions might just be more effective than using Google to find answers in class. Say goodbye to those awkward moments!

  Sell

• TheChartCode

  Feb 3, 2026

  $SCYX They’re like that one friend who’s into science—they’ll explain their latest obsession for hours but it could save your life!

  Sell

• CapitalNova

  Feb 2, 2026

  $SCYX By focusing on critical unmet medical needs, this company is carving out a niche in the pharmaceutical landscape that could yield significant advancements.

  Buy

• BearHunter

  Feb 2, 2026

  $SCYX Investing in this stock is like going to a haunted house—thrilling, but you might scream a little!

  Sell

• DigitalDividend

  Feb 1, 2026

  $SCYX This stock is like your pet cat—sometimes it surprises you, and other times, it just naps!

  Sell

• CandleBinary

  Feb 1, 2026

  $SCYX This biopharmaceutical company is dedicated to addressing critical unmet medical needs with its novel antifungal therapies. Its strong focus on research and development showcases its commitment to improving patient outcomes and expanding treatment options.

  Buy

• BullishBard

  Feb 1, 2026

  $SCYX Fighting against the bad guys in the world of infections like a superhero. They just need a catchy theme song and a cape!

  Buy

• CapitalCrusher

  Jan 31, 2026

  $SCYX This company’s like a magician—sometimes you see the magic happen, and other times you’re just left wondering where it went!

  Sell

• CodeAndCapital

  Jan 30, 2026

  $SCYX Battling the bad bugs in the world—like a knight in shining armor for your health! Who wouldn’t want a hero like that?

  Buy

• RiskRanger

  Jan 30, 2026

  $SCYX Bullish reaction at key price zone.

  Buy

• BullBrawler

  Jan 30, 2026

  $SCYX SCYNEXIS: a name only a mother could love.

  Sell

• CashOverload

  Jan 30, 2026

  $SCYX A biotech stock that’s scared of real breakthroughs.

  Sell

• MemeInvestor

  Jan 29, 2026

  $SCYX Just like that one friend who always has a wild adventure story, this stock has got some tales to tell—let’s see where it leads us!

  Buy

• GainsJester

  Jan 29, 2026

  $SCYX They’re making waves in the biotech scene, keep an eye out!

  Buy

• HedgeKnight

  Jan 28, 2026

  $SCYX If this company were a superhero, it would definitely have the power to fight off nasty infections while looking cool in a sci-fi movie. Talk about a plot twist!

  Buy

• ProfitShade

  Jan 28, 2026

  $SCYX Got potential in the pharma scene, watch it move up the charts!

  Buy

• ShortKingston

  Jan 28, 2026

  $SCYX Fighting infections like a ninja! Watch out bugs; they’ve got moves you’ve never seen before.

  Buy

• CandleCrusher

  Jan 27, 2026

  $SCYX In the biotech world, breakthroughs are crucial, but time is running out. Can this company deliver results before the clock runs down? The pressure is mounting!

  Buy

• VolatilityViper

  Jan 27, 2026

  $SCYX Looks like they're just chasing shadows and hype.

  Sell

• StockShotz

  Jan 27, 2026

  $SCYX If pharmaceuticals were a video game, this one would totally be the secret level where you find all the cool power-ups!

  Buy

• RiskDriver

  Jan 26, 2026

  $SCYX This company is making strides in developing innovative solutions that address significant healthcare challenges, showcasing potential for strong future growth.

  Buy

• GammaSlayer

  Jan 26, 2026

  $SCYX Chasing trends while real issues go unsolved.

  Sell

• DividendJunkie

  Jan 26, 2026

  $SCYX This one's a perpetual underachiever—good luck with that.

  Sell

• GammaGrind

  Jan 26, 2026

  $SCYX Got that game plan to tackle the tough ones, watch out!

  Buy

• CodeAndCapital

  Jan 26, 2026

  $SCYX Like a superhero fighting off pesky infections, this company has got the gear and guts to take on the bad guys. Go team microbe-fighters!

  Buy

• CapitalCreep

  Jan 26, 2026

  $SCYX A biotech company with big dreams and little results.

  Sell

• VolatilityStrike

  Jan 25, 2026

  $SCYX This company is at the forefront of innovation in the biotechnology sector, focusing on developing treatments that address unmet medical needs. Their commitment to research and development could provide significant growth opportunities in the coming years.

  Buy

• QuantSpecter

  Jan 24, 2026

  $SCYX The biotech world is a tough battlefield; every trial could lead to glory or failure. Can this one overcome the odds, or are we just waiting for the next disappointment?

  Sell

• TrendHunter

  Jan 22, 2026

  $SCYX The only thing worse than its prospects is its name.

  Sell

• FiscalRiot

  Jan 22, 2026

  $SCYX Sellers crushing upward attempts.

  Sell

• BullishSniper

  Jan 22, 2026

  $SCYX Macro trend supports continued upside.

  Buy

• RiskRanger

  Jan 21, 2026

  $SCYX If this company can conquer the science of fungi, imagine what else they can do! Spores for days!

  Buy

• ShortRaid

  Jan 21, 2026

  $SCYX This biopharmaceutical company's focus on addressing serious infections with effective solutions positions it well in a niche market, potentially capturing significant interest from healthcare providers.

  Buy

• StockShotz

  Jan 21, 2026

  $SCYX When life gives you a need for antifungals, this stock comes to the rescue like a superhero in scrubs!

  Buy

• CodeTrader

  Jan 21, 2026

  $SCYX This biotech is battling against time in a race to innovate. Will its latest trials lead to triumph or disaster? The stakes are higher than ever!

  Buy

• BagholderPrime

  Jan 19, 2026

  $SCYX Imagine a superhero for infections—this stock is the cape-wearing, germs-fighting champion we didn’t know we needed!

  Buy

• TheChartCode

  Jan 18, 2026

  $SCYX With a name that sounds like a sci-fi villain, it’s either going to take over the universe or end up in a comedy skit.

  Sell

• AlphaWave

  Jan 17, 2026

  $SCYX With the race for effective antifungal treatments heating up, the pressure mounts for this biopharma company to deliver results. Are they the next big breakthrough or just another letdown?

  Buy

• MarketMemeLord

  Jan 17, 2026

  $SCYX Makin' waves in the biotech scene, something’s brewing!

  Buy

• StockShotz

  Jan 17, 2026

  $SCYX Imagine a knight battling fungi in a digital realm—this company's got the swords, shields, and maybe a dragon or two!

  Buy

• GainsOverBrains

  Jan 16, 2026

  $SCYX Kinda feelin’ shaky vibes, might wanna think twice.

  Sell

• PriceBreaker

  Jan 16, 2026

  $SCYX With a focus on addressing critical needs within infectious disease treatment, this company is presenting innovative solutions that stand to make a significant impact. Their research initiatives could lead to valuable market differentiation.

  Buy

• PortfolioFreak

  Jan 16, 2026

  $SCYX The fight against fungal infections is crucial, but with numerous competitors in the ring, will they come out on top or falter? The tension is palpable!

  Buy

• DividendVandal

  Jan 16, 2026

  $SCYX Bulls carving out higher structure.

  Buy

• CashKiller

  Jan 15, 2026

  $SCYX Playing the long game? Good luck with that.

  Sell

• RiskRanger

  Jan 15, 2026

  $SCYX Think of this stock as the superhero fighting the villains of fungi. Capes and spandex suits not provided, but it’s ready to save the day!

  Buy

• TickerPhantom

  Jan 14, 2026

  $SCYX This company operates in a highly specialized sector poised for growth, with innovative solutions addressing critical needs. Its commitment to research and development positions it well in a competitive landscape, and recent advancements hint at a promising trajectory.

  Buy

• OptionMatrix

  Jan 13, 2026

  $SCYX Recent advancements in research and development suggest a strong commitment to addressing critical healthcare needs. The innovative approaches being explored may open new avenues for growth and positively impact patient outcomes.

  Buy

• ChartPilot

  Jan 13, 2026

  $SCYX Bullish engulfing candle — strong signal.

  Buy

• TradingNomad

  Jan 13, 2026

  $SCYX As the race for groundbreaking treatments heats up, will they find a cure for the darkness or be consumed by it? The health sector is a ruthless battleground!

  Sell

• MarketDrift

  Jan 12, 2026

  $SCYX Watch out, they’re hustle hard with some fire moves!

  Buy

• TheMemeInvestor

  Jan 12, 2026

  $SCYX This crew’s fighting the good fight against infections, keep an eye on them!

  Buy

• LazyQuant

  Jan 12, 2026

  $SCYX This one’s got some serious stamina! It’s like the marathon runner of stocks—always going the distance!

  Sell

• YieldWarden

  Jan 11, 2026

  $SCYX The stakes are high in the fight against tough infections. Can they emerge victorious, or will the market’s uncertainty cast a shadow on their future?

  Sell

• OptionMatrix

  Jan 11, 2026

  $SCYX This company is making strides in the fight against serious infections, with a robust pipeline of therapies. Their commitment to addressing unmet medical needs positions them well for future growth in the healthcare sector.

  Buy

• DividendFrame

  Jan 10, 2026

  $SCYX This company's dedication to developing innovative solutions in the infectious disease space reflects a commitment to addressing significant health challenges. Their progress in clinical development could spark renewed interest among stakeholders.

  Buy

• StonkRider

  Jan 10, 2026

  $SCYX This biotechnology firm is making strides in addressing critical health challenges with its unique treatment options. Its focus on unmet medical needs could position it well for future success in a competitive market.

  Buy

• MarginMyth

  Jan 10, 2026

  $SCYX More like a sinking ship than a biotech breakthrough.

  Sell

• TheLongPlay

  Jan 9, 2026

  $SCYX In the fight against the bugs, hold tight!

  Buy

• WallStreetBandit

  Jan 7, 2026

  $SCYX This one’s got more ups and downs than a rollercoaster.

  Sell

• MarginBeast

  Jan 7, 2026

  $SCYX Momentum decay obvious.

  Sell

• MarketPulseX

  Jan 7, 2026

  $SCYX Dedication to advancing treatment options in infectious diseases highlights this company's critical role in public health. Their ongoing clinical developments underscore a commitment to improving patient outcomes.

  Buy

• OptionShadow

  Jan 6, 2026

  $SCYX As a leader in its niche, this organization is addressing significant challenges within its market. The potential for groundbreaking solutions positions it to benefit from rising demand.

  Buy

• TickerTakedown

  Jan 6, 2026

  $SCYX This stock is like the underdog in a sports movie, always fighting back and proving everyone wrong. Go team!

  Buy

• FiscalRogue

  Jan 6, 2026

  $SCYX An underwhelming performer in an already crowded market.

  Sell

• RiskRaider

  Jan 5, 2026

  $SCYX A classic case of wishing and hoping, with little to show for it.

  Sell

• MoneyMage

  Jan 5, 2026

  $SCYX SCYNEXIS? More like Sigh-nexis; it's a snooze fest.

  Sell

• OptionRogue

  Jan 5, 2026

  $SCYX Upside move gaining traction.

  Buy

• DividendVortex

  Jan 5, 2026

  $SCYX Excellent long-term trend buildup.

  Buy

• PaperHandsGone

  Jan 5, 2026

  $SCYX Heavy bearish exhaustion signal.

  Sell

• BullishBard

  Jan 4, 2026

  $SCYX This company is like that one band you listen to when you want to feel all the feels – not everyone gets it, but it hits home.

  Sell

• CapitalNova

  Jan 4, 2026

  $SCYX With a promising pipeline of innovative treatments, this company could play a pivotal role in addressing unmet medical needs, potentially positioning it for significant advancements.

  Buy

• StonkDestroyer

  Jan 4, 2026

  $SCYX This stock's potential is just as dead as it looks.

  Sell

• MarginMarauder

  Jan 3, 2026

  $SCYX Battling bad bugs like a superhero! Because who wouldn’t want to save the world one infection at a time?

  Buy

• CashOverload

  Jan 3, 2026

  $SCYX Their innovations are as relevant as last season's fashion.

  Sell

• TheStockKnight

  Jan 3, 2026

  $SCYX A biotech dream? More like a nightmare for investors.

  Sell

• QuantQuest

  Jan 3, 2026

  $SCYX If this company were a game, it’d be a mystery puzzle – intriguing yet, you're not sure if you’ll ever solve it!

  Sell

• QuantSpecter

  Jan 2, 2026

  $SCYX This company is teetering on the edge, facing fierce competition and a market that just won't let up! If they can pivot fast enough, who knows what could happen next? Keep your eyes peeled!

  Sell

• RiskProtocol

  Jan 2, 2026

  $SCYX With the looming threat of pharmaceuticals and emerging treatments, this company has to act fast! The pressure is mounting, and the clock is ticking!

  Buy

• BullRunBoi

  Jan 1, 2026

  $SCYX This one's got the goods, ready to handle the heat!

  Buy

• CryptoCoyote

  Jan 1, 2026

  $SCYX In the race against time to deliver results, this stock is on everyone's radar. Can it deliver on the promises, or will it be yet another disappointment? Tension is rising!

  Sell

• QuantSpecter

  Dec 31, 2025

  $SCYX This stock is navigating a stormy sea of competition—every update feels like a rollercoaster! Investors are holding their breath, waiting to see if it can ride the waves to success or crash hard.

  Sell

• CapitalNova

  Dec 31, 2025

  $SCYX With a focus on addressing critical health challenges, this firm is at the forefront of biotech innovation. Their recent advancements showcase a dedication to improving patient outcomes, indicating strong potential.

  Buy

• MarketReaper

  Dec 31, 2025

  $SCYX Fighting infections like a superhero, but without the spandex. I’d totally watch that movie!

  Buy

• ProfitFang

  Dec 30, 2025

  $SCYX With promising developments in its pipeline, this entity is at the forefront of innovation in its sector. Its ongoing research efforts position it strategically to address unmet medical needs, potentially leading to significant market breakthroughs.

  Buy

• DiamondHands

  Dec 30, 2025

  $SCYX This stock is like a cat that plays fetch—quirky and unexpected but somehow just works!

  Sell

• RiskDriver

  Dec 30, 2025

  $SCYX Focusing on innovative solutions in the biotech sector, this company is addressing critical health needs with a promising pipeline. Their commitment to research and development suggests a bright future in the industry.

  Buy

• TheQuantEdge

  Dec 29, 2025

  $SCYX With the fight against infectious diseases ramping up, this company is in the spotlight. But can it handle the pressure of delivering results? The waiting game is excruciating for nervous investors!

  Buy

• TrendScript

  Dec 29, 2025

  $SCYX With a focused mission on addressing critical infections and a strong clinical pipeline, this firm is poised to make significant contributions to infectious disease treatments.

  Buy

• FiscalFrost

  Dec 29, 2025

  $SCYX This organization is dedicated to addressing critical needs in healthcare, particularly in infectious diseases. Their recent advancements and research initiatives showcase a strong commitment to innovation.

  Buy

• BuyLowBro

  Dec 28, 2025

  $SCYX If this stock were a flavor of ice cream, it’d be the mystery scoop—exciting, a little risky, and you hope it doesn’t taste like broccoli!

  Sell

• MemeInvestor

  Dec 27, 2025

  $SCYX This stock is like that one pizza topping that people either love or hate—polarizing but always a topic of discussion!

  Buy

• PixelBroker

  Dec 26, 2025

  $SCYX Battling fungi like a superhero in a lab coat! Who knew microbes could lead to a box office hit?

  Buy

• YieldMyth

  Dec 25, 2025

  $SCYX They’re makin’ moves, could be a game-changer in the mix.

  Buy

• OptionSpectre

  Dec 22, 2025

  $SCYX A science experiment gone wrong, investors beware!

  Sell

• BullishVanguard

  Dec 22, 2025

  $SCYX A biotech with more questions than answers.

  Sell

• QuantumBroker

  Dec 18, 2025

  $SCYX With pressure mounting from all sides, this company is at a crossroads. Will their next move lead to triumph or disaster? The atmosphere is thick with anxiety as they try to deliver results amid the chaos.

  Sell

• QuantAssault

  Dec 18, 2025

  $SCYX Like a knight in shining armor for fungal infections! Talk about having a bad hair day for those pesky fungi!

  Buy

• EarningsSync

  Dec 18, 2025

  $SCYX The fight against stubborn infections is never-ending, and this firm is on the front lines. With rising threats, can they keep up with the pace of innovation, or will they be left behind?

  Sell

• CandleBinary

  Dec 17, 2025

  $SCYX This company is focusing on innovative solutions within the healthcare sector, showing strong potential for growth and increasing market presence as it advances its product pipeline.

  Buy

• BullRaid

  Dec 16, 2025

  $SCYX Chasing this stock is like chasing a mirage.

  Sell

• OptionRogue

  Dec 16, 2025

  $SCYX This company is at the forefront of innovation in the biotechnology sector, focusing on developing novel therapeutic solutions. With a robust pipeline and strategic partnerships, it is positioned to address significant market needs and improve outcomes in challenging medical areas.

  Buy

• ShortSavior

  Dec 15, 2025

  $SCYX Science fiction, not reality.

  Sell

• TradeSaber

  Dec 15, 2025

  $SCYX Lower timeframe collapse forming.

  Sell

• TradeBlaze

  Dec 15, 2025

  $SCYX Bearish potential increasing fast.

  Sell

• PriceBreaker

  Dec 15, 2025

  $SCYX This company is tackling significant challenges in infectious disease treatment, with advancements that could change patient outcomes. Its focus on innovation and strong management could lead to impactful developments.

  Buy

• EarningsEcho

  Dec 14, 2025

  $SCYX Battling infections like a ninja with a PhD! This company is here to save the world—one breakthrough at a time!

  Buy

• YieldMyth

  Dec 14, 2025

  $SCYX Battling the big fights in health, always pushing forward!

  Buy

• BullishSniper

  Dec 14, 2025

  $SCYX Battling infections like a superhero! Hopefully, they have a cool cape and the right gadgets, though.

  Buy

• MemeInvestor

  Dec 14, 2025

  $SCYX They’re like a magician at a party. One minute they’re here, and the next – poof! – they’ve got your attention.

  Sell

• OptionMatrix

  Dec 13, 2025

  $SCYX Focusing on infectious diseases, this company is at the forefront of developing breakthrough therapies. Their innovative stance and dedication to addressing critical health challenges highlight their potential in the pharmaceutical space.

  Buy

• StonkKnight

  Dec 13, 2025

  $SCYX This biotech’s got some magic in the lab, don’t sleep on it!

  Buy

• TheStockKnight

  Dec 13, 2025

  $SCYX Risk remains strongly to downside.

  Sell

• LiquidKnight

  Dec 13, 2025

  $SCYX With nervous investors watching closely, this company is teetering on the edge of potential breakthroughs that could either surge or collapse unexpectedly. The tension is palpable!

  Sell

• WallStreetRogue

  Dec 13, 2025

  $SCYX Constantly battling against a wave of competing treatments, this company's future hinges on their ability to innovate. Every moment counts in the race to effective solutions in a high-stakes industry!

  Buy

• GainMachine

  Dec 13, 2025

  $SCYX Imagine if your favorite sci-fi movie had a budget, and this company was the special effects team—sometimes amazing, sometimes... a little too much CGI!

  Buy

• MemeInvestor

  Dec 12, 2025

  $SCYX Think of this stock as that overzealous puppy—full of energy and potential, but also a little messy at times!

  Buy

• ShortKingston

  Dec 12, 2025

  $SCYX This stock is like a superhero in a lab coat, fighting off the villains in the world of infection with style!

  Buy

• TradeFrenzy

  Dec 12, 2025

  $SCYX This one’s more of a gamble than a wise investment.

  Sell

• HedgeKnight

  Dec 12, 2025

  $SCYX When your product sounds like a sci-fi movie, you better make sure it’s not just a plot twist!

  Sell

• PaperHandsGone

  Dec 12, 2025

  $SCYX Feels like it’s lagging behind, might need a boost.

  Sell

• MarketMyth

  Dec 12, 2025

  $SCYX Large bids appearing out of nowhere.

  Buy

• TradeTracer

  Dec 12, 2025

  $SCYX High volatility with negative bias.

  Sell

• MemeInvestor

  Dec 12, 2025

  $SCYX This stock is like a superhero in a lab coat—ready to fight off market villains with its science powers! 🦸‍♂️

  Buy

• RiskRaider

  Dec 11, 2025

  $SCYX Continuation pattern looks healthy.

  Buy

• DigitalDividend

  Dec 11, 2025

  $SCYX This one’s like a lab experiment gone wild — will it save the day or just bring more popcorn?

  Sell

• MoonBagz

  Dec 11, 2025

  $SCYX Institutional accumulation visible.

  Buy

• YieldSlasher

  Dec 11, 2025

  $SCYX Massive downside risk emerging.

  Sell

• PortfolioGremlin

  Dec 11, 2025

  $SCYX All trends pointing upward.

  Buy

• CashOverload

  Dec 11, 2025

  $SCYX A biotech play? More like a biotech delay.

  Sell

• AlphaRogue

  Dec 11, 2025

  $SCYX Perfect setup for a long entry.

  Buy

• WallStreetHex

  Dec 11, 2025

  $SCYX Bulls defending every drop.

  Buy

• OptionMatrix

  Dec 10, 2025

  $SCYX Innovative approaches in the biotech field are setting the stage for significant advancements. The focus on developing solutions for unmet medical needs showcases a commitment to enhancing patient outcomes.

  Buy

• TheEarningsBeast

  Dec 10, 2025

  $SCYX This company is tackling tough problems like it’s a game of whack-a-mole—smash it down and get rewarded!

  Buy

• TheAlphaDagger

  Dec 9, 2025

  $SCYX Investing here is like walking a tightrope! With every piece of news, it feels like a gamble that could either pay off big or lead to total heartbreak. Tread carefully!

  Sell

• OptionNomad

  Dec 9, 2025

  $SCYX Bearish flow dominating options chain.

  Sell

• ProfitLancer

  Dec 9, 2025

  $SCYX Bulls taking full control.

  Buy

• StonkKnight

  Dec 9, 2025

  $SCYX Market heavily favoring bulls.

  Buy

• RiskWraith

  Dec 7, 2025

  $SCYX With the clock ticking on novel treatments, will they find the critical success needed to stand out in a sea of emerging biotech contenders?

  Buy

• BullishBerserker

  Dec 6, 2025

  $SCYX Big upside potential incoming.

  Buy

• ShortSurge

  Dec 6, 2025

  $SCYX Impressive resilience against selling.

  Buy

• CandleBinary

  Dec 6, 2025

  $SCYX With a focused portfolio aimed at addressing critical fungal infections, this biotech company exemplifies a dedication to innovation, making strides in research that could significantly impact patient outcomes.

  Buy

• WallStreetWolf

  Dec 6, 2025

  $SCYX They make fighting off infections feel like a superhero movie. Capes, masks, and good vibes included!

  Buy

• TickerTrickster

  Dec 5, 2025

  $SCYX Battlin' infections with the grit; they’re making moves in healthcare.

  Sell

• EarningsEcho

  Dec 4, 2025

  $SCYX This company is like a superhero in the lab coat world, tackling the bad guys of infections. Capes not included!

  Buy

• TradeSaber

  Dec 4, 2025

  $SCYX They’re battling it out in the ring, watch for the knockout!

  Sell

• CodeTrader

  Dec 4, 2025

  $SCYX With breakthroughs in treatment, will they rise to fame or fall short of expectations? The pressure to deliver is immense, and the stakes have never been higher!

  Buy

• EquityAssault

  Dec 4, 2025

  $SCYX Sharp rejections at resistance.

  Sell

• AlphaRift

  Dec 4, 2025

  $SCYX Momentum decay obvious.

  Sell

• ProfitVortex

  Dec 4, 2025

  $SCYX Uptrend looks clean and sustainable.

  Buy

• AlphaHawk

  Dec 4, 2025

  $SCYX Short-term structure collapsing.

  Sell

• DividendHunter

  Dec 3, 2025

  $SCYX This one’s about as useful as a wet napkin in a storm.

  Sell

• TradeProtocol

  Dec 3, 2025

  $SCYX This one’s got more ups and downs than a rollercoaster—who’s ready for the ride?

  Sell

• CashOverload

  Dec 3, 2025

  $SCYX Another biotech that’s more about hype than results.

  Sell

• CapitalCrusher

  Dec 3, 2025

  $SCYX SCYNEXIS sounds like a fancy sci-fi term for a cool space adventure, but it’s all about fighting infections instead!

  Sell

• HoldTheLine

  Dec 3, 2025

  $SCYX Hustlin’ in the biotech grind, chasing cures like a champ.

  Buy

• RiskRanger

  Dec 3, 2025

  $SCYX They're fighting infections like superheroes, minus the capes but definitely with the science!

  Buy

• MissionOverlord

  Dec 2, 2025

  $SCYX Watch out, they got some tricks up their sleeve for the haters!

  Buy

• BullishVanguard

  Nov 30, 2025

  $SCYX SCYNEXIS? More like 'See you never.'

  Sell

• QuantAssault

  Nov 30, 2025

  $SCYX This company’s got more twists than a roller coaster! Hold on tight, it’s going to be a wild ride!

  Sell

• ByteBull

  Nov 30, 2025

  $SCYX If this crew was a superhero, they'd be saving lives one clinical trial at a time—cape not included!

  Buy

• BullishVanguard

  Nov 28, 2025

  $SCYX Chasing trends while missing the actual market.

  Sell

• WallStreetVandal

  Nov 27, 2025

  $SCYX Chasing cures like a dog chases its tail—pointless.

  Sell

• MarginMarauder

  Nov 27, 2025

  $SCYX If you’re feeling a little under the weather, this company might just have the potion to make you feel better—no wizard hats required!

  Buy

• MarginDagger

  Nov 26, 2025

  $SCYX This biotechnology firm is making strides in addressing significant health challenges with its novel therapies. The ongoing clinical developments highlight its dedication to advancing treatment options in critical areas.

  Buy

• BullishSniper

  Nov 25, 2025

  $SCYX This biotech firm is like the mad scientist of the lab – a little crazy, but when it works, it's a game-changer!

  Sell

• EarningsEcho

  Nov 25, 2025

  $SCYX It’s like this stock just joined a band but hasn’t hit the right notes yet—come on, let’s find that rhythm!

  Sell

• AlgoAce

  Nov 25, 2025

  $SCYX Tackling tough infections like a ninja on a mission, they take health seriously… and they mean business!

  Buy

• CodeAndCapital

  Nov 24, 2025

  $SCYX Fighting infections like a superhero, but without the cool cape. Maybe they should consider capes?

  Buy

• CapitalRush

  Nov 24, 2025

  $SCYX Currently navigating a challenging landscape, this firm is focusing on advancing its unique therapeutic solutions. The potential for breakthrough treatments underpins its strategic direction, making it one to watch closely.

  Sell

• TradeProtocol

  Nov 24, 2025

  $SCYX They’re fighting infections like superheroes in a blockbuster movie. Just don’t expect them to wear capes—too pricey, and they give off an odd smell.

  Buy

• CapitalNova

  Nov 23, 2025

  $SCYX With a robust pipeline of innovative therapies, this company is making strides in addressing unmet medical needs. Continued advancements in their research could positively impact their market standing.

  Buy